Implications of obesity for drug therapy: limitations and challenges.
about
Protocols in the management of critical illnessObesity Is Not Associated with Antimicrobial Treatment Failure for Intra-Abdominal Infection.Obesity and the risk and outcome of infection.Pharmacokinetics of Antimicrobials in Obese Children.Molecular matchmaking between the popular weight-loss herb Hoodia gordonii and GPR119, a potential drug target for metabolic disorderDesigning drug regimens for special intensive care unit populations.Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjectsDrug Dosing and Pharmacokinetics in Children With Obesity: A Systematic ReviewGaps in Drug Dosing for Obese Children: A Systematic Review of Commonly Prescribed Emergency Care Medications.Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescentsPediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing.Intestinal removal of free fatty acids from hosts by Lactobacilli for the treatment of obesity.Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model.Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically Ill Patients.Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients.Impact of obesity on drug metabolism and elimination in adults and children.Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults.The effects of gastric bypass surgery on drug absorption and pharmacokinetics.Identifying determinants of variability to tailor aspirin therapy.Clinical management of obese patients with cancer.Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review.Altered drug disposition following bariatric surgery: a research challenge.Impact of special patient populations on the pharmacokinetics of echinocandins.Improving Medication Dosing in the Obese Patient.Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study.Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients.Effect of body mass index on overall survival of patients with allogeneic hematopoietic stem cell transplantation.The fat and the bad: Mature adipocytes, key actors in tumor progression and resistance.Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.A high BMI is a risk factor in younger patients with de novo acute myelogenous leukemia.Effect of a high-fat diet on the hepatic expression of nuclear receptors and their target genes: relevance to drug disposition.The clinical pharmacology of obesity.Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma.Obesity and its impact on drug therapy: are we ready for this change?Dose capping of plerixafor in patients weighing more than 100 kg at one vial led to successful mobilization outcomes and significant cost savings.Body mass index and bioelectrical impedance phase angle as potentially modifiable nutritional markers are independent risk factors for outcome in allogeneic hematopoietic cell transplantation.Drug dosing in obese adults.Can body mass index predict the outcome of diffuse large B-cell lymphoma? A single-center retrospective study in China.Development and Characterization of a Novel Congenic Rat Strain for Obesity and Cancer Research.
P2860
Q27002502-782AD1BA-1461-4BB7-ADCA-901A5A033084Q30277073-5E3026A9-D28D-4627-8842-10F39B38DBEBQ30416191-DFBE0682-6154-47FB-AF62-37F540E11BC5Q33855312-2B7A0475-9C86-4D10-9D29-B8788CEA05C0Q34407783-C32AEB3C-E836-413D-AB44-8C35716D3E69Q35544079-41F2E2B6-B291-4750-A7E8-54D484DEE47FQ35746176-385591A3-2191-4B42-ABC6-3BB2A8F0E291Q35828378-EAEBC3C1-3F40-47F5-BAF8-056FD37326F4Q36100620-99EB9801-3A1A-4ACF-8F2A-6707B3839D5CQ36243689-4BB3E889-429F-46B5-9468-1A022BA49DC6Q36247129-F6F9BAFE-9FB1-46FA-A6D1-40F670F7C72DQ36694416-F40DDA9F-836B-4732-88E8-AF159D52D5B8Q36887757-59D04AA4-D9BF-46C6-9516-BF15F9E9FC5BQ37120024-58D254D9-CB0E-4C2A-B62C-9E1864818456Q37358623-D63789E8-63CF-4F8F-9295-3361245EAB60Q37997025-650E1152-C80B-4277-A1E6-C38C4A4F3EE3Q38019839-D0D9B3BE-BE4D-4D5E-B0E1-E80A922A17A9Q38045375-12B3EC66-68B6-4E6F-B778-6DA0B8392C74Q38087384-B3383C04-1809-4511-99E7-7404A68F409DQ38121736-6D025CD3-5E08-4D27-A7BE-875868398A05Q38247400-4DB2FE48-BBF5-4032-8909-9F4D8E20AB41Q38381805-C6B2E5DD-C000-4DD1-B831-66868783EBDCQ38462784-C0AB8A02-14E0-47D0-B5A7-B8A745E69680Q38947388-C4AEC928-9D3D-482D-92E8-9550FAFD064BQ39033125-3E92D54C-12B1-4D21-82C9-FB49F80E93BFQ39040314-E77E3D46-DB5E-4B88-9485-3457592E534EQ39143601-594F7AAD-5A4E-4652-8F4D-5E4874AFE330Q39356609-25291EDA-4C91-42BE-AD07-83273FEFFB97Q39484436-5A6DFD46-33D9-4AE4-976E-9857F8061517Q41139120-D6E7BE81-7EE2-4D20-97CE-2DC4CBA3C4B8Q41479185-8CA05691-8CE3-40DA-BDBF-D2C2B19040B7Q41542803-40B6DAF0-E34B-4B30-94B9-40576D749C45Q42416620-B66B0C21-FB52-4C01-866A-D5C067C5624CQ45217243-5465EB95-2BD3-4D55-9DEF-C8FD2E884E50Q46260355-43046ABD-1F79-4DDF-B78A-2C906F04287BQ46654811-9FBC0C80-B286-43F8-BAC5-70DB5E65A7EFQ46866626-7F79012E-7C25-4327-B101-109CA4AAEA6AQ47154923-AF457D33-AABC-40EB-961F-27BC6382F668Q47940583-40EEDB96-777C-4014-8988-81307A13DCBDQ48290155-0746E0C2-39FC-45A8-B6E5-EBB45D91087A
P2860
Implications of obesity for drug therapy: limitations and challenges.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Implications of obesity for drug therapy: limitations and challenges.
@en
Implications of obesity for drug therapy: limitations and challenges.
@nl
type
label
Implications of obesity for drug therapy: limitations and challenges.
@en
Implications of obesity for drug therapy: limitations and challenges.
@nl
prefLabel
Implications of obesity for drug therapy: limitations and challenges.
@en
Implications of obesity for drug therapy: limitations and challenges.
@nl
P2093
P2860
P356
P1476
Implications of obesity for drug therapy: limitations and challenges.
@en
P2093
C G Sahajwalla
I Zadezensky
J Vaidyanathan
P2860
P356
10.1038/CLPT.2011.104
P407
P577
2011-06-01T00:00:00Z